TABLE 3.
Comparison of regimens utilizing alemtuzumab
| Reference | Number of patients | Distal lymphodepletion (day −21 through day −11) | Proximal lymphodepletion (day −10 through day 0) | Disease free survival (%) | Acute GVHD (%) | Chronic GVHD (%) |
|---|---|---|---|---|---|---|
| Alem-TBI | 58 | None | Alem | 87 | 0 | 0 |
| Pento-Cy-Alem-TBI | 26 | Pento-Cy | Alem | 96 | 8 | 0 |
| Shenoy20 | 16 | Alem | Flu-Mel | NAa | 28 | 0 |
| Sahdev27 | 9 | None | Alem-Flu-Mel | 67 | 11 | 0 |
| Sahdev27 | 16 | Alem | Flu-Mel | 94 | 43 | 25 |
Abbreviations: Alem, alemtuzumab; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft versus host disease; Mel, melphalan; NA, not applicable; Pento, pentostatin; TBI, total body irradiation.
a
Various non-malignant disorders were treated under this protocol. 75% of patients experienced stable, improved, or cured disease.